EPAM Enters Earnings Day With Shorts Trimming and Analysts Raising Targets

EPAM Systems reports Q3 results on November 5 with an unusual setup: short sellers have been quietly cutting positions over the past week even as the stock sits nearly 11% short of its free float, and analysts have spent the past ten days raising targets by amounts that would have looked implausible three months ago.

Short interest, at 10.9% of the free float, remains elevated by any standard, but the direction has shifted. Bears trimmed roughly 2.1% of their positions over the past week, bringing short shares to around 6.0 million from a recent peak of 7.8 million in late September. The lending market is in no way stressed: availability has actually loosened, with nearly five shares available to borrow for every one already on loan, well above the 52-week tightest point of roughly 1.7 shares available per borrowed share. Cost to borrow ticked up about 11% on the week but remains a negligible 0.55%, a level that creates no pressure on existing shorts. The ORTEX short score has drifted lower, to 58.3 from about 59.9 at the end of October, reflecting the modest reduction in short pressure. Availability is loosening precisely as shorts pare back, a combination that does not suggest a forced squeeze.

Options tell a different story from the positioning camp. The put/call ratio has dropped sharply to 1.0, nearly 1.7 standard deviations below its 20-day mean of 1.23, and well below the 52-week high of 1.65 reached when hedging demand was heaviest. That shift from heavy put demand toward a more balanced book happened fast: the PCR ran above 1.35 for most of late October before collapsing in the final two sessions. Options traders have dialled back the bearish protection they were carrying into the week, which is a notable change given that EPAM's last earnings print, the August Q2 report, produced an 11% single-day drop and a further 7.6% loss over the subsequent five sessions.

The analyst community has moved with unusual speed ahead of the print. Morgan Stanley's James Faucette lifted his target to $140 from $97 on November 4, maintaining an Equal-Weight rating but acknowledging a materially changed price ceiling. Guggenheim raised its Buy target to $160 from $140 on November 2. Citigroup and Wells Fargo both raised targets on October 26, to $140 and $156 respectively. Every one of those revisions came from a base set after August's post-earnings cuts, when firms including JP Morgan, TD Cowen and Susquehanna slashed targets following the Q2 miss. The mean target now stands at $131, fractionally below the current price of $138, which means consensus has not fully caught up with the stock's 28% recovery over the past month. The bull case centres on improving demand signals in Europe and life sciences, AI-native revenue tracking toward a $600 million full-year target, and better gross margins in the second half. The bear case points to a CY26 revenue growth outlook that was cut by 125 basis points to 2% to 3%, ongoing North American softness, and AI token costs compressing margins at the edges. Valuation multiples have expanded meaningfully: the price/earnings ratio has risen by 2.0 points over the past 30 days, and EV/EBITDA has edged lower as cash has built. The earnings yield factor ranks in the 78th percentile and EV/EBIT in the 89th, suggesting the market is not yet paying a growth premium for the recovery story.

Institutional ownership corroborates the recent buying pressure. BlackRock added 2.5 million shares in Q3 to reach 12.9% of the company, its largest disclosed holding. Columbia Management added 1.7 million shares to reach 10.6%. Capital World Investors has trimmed from 13.4% to 9.4% since February, the most significant institutional exit in the register. No activist 13D filings are on record; all major holders are on passive 13G schedules. Wikipedia page views for EPAM have spiked to 3.1 standard deviations above the 90-day norm, as of October 22, the most visible proxy for rising retail attention in the available data.

Insider activity in the latest filings is minimal in dollar terms. Six executives, including CEO Balazs Fejes and CFO Jason Peterson, acquired fractional shares on October 31 at $95.48, totalling a few hundred dollars each in what appear to be routine plan-based allocations rather than open-market conviction purchases. Net insider activity over the 90-day window is flat. The price at which those shares were acquired, nearly $43 below where the stock closed on November 3, illustrates how quickly the stock has moved in the past month.

The November 5 print is the clearest near-term event: the last time EPAM reported, the stock shed 11% on the day, and the question now is whether the analyst target resets, loosening short positioning, and a more balanced options book reflect genuine confidence or simply relief that the worst of the guidance resets may be behind it.